Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium
The radioactive ingredients that make theranostics work come from a small number of ageing nuclear reactors, generators and accelerators around the world. A shortage anywhere in that chain delays cancer scans and treatments; new non-uranium and accelerator-based production lines are being built to fix that, but they take years and hundreds of millions of dollars.
Overview
For decades the world's molybdenum-99 (the parent of technetium-99m, the workhorse of conventional nuclear medicine) came almost entirely from a handful of ageing research reactors using highly enriched uranium targets, concentrated in Canada, the Netherlands, Belgium, France and South Africa. When Canada's NRU reactor and the Netherlands' HFR both went offline for repairs in 2009-2010, the resulting shortage disrupted nuclear medicine services worldwide and triggered a policy response.
The US response, formalised in the American Medical Isotope Production Act of 2012, funded non-uranium domestic production. NorthStar Medical Radioisotopes' RadioGenix System, producing molybdenum-99 without highly enriched uranium via neutron capture at the University of Missouri Research Reactor, received FDA approval in February 2018, the first domestic Mo-99 production in roughly three decades. Lutetium-177 demand then rose sharply once Lutathera (2018) and Pluvicto (2022) were approved, straining the same reactor capacity and the enriched ytterbium-176 supply used for no-carrier-added production.
The newest constraint is actinium-225 for targeted alpha therapy, historically harvested in gram quantities from thorium-229 stockpiles. TerraPower Isotopes announced commercial-scale, weekly actinium-225 production in October 2024 using a natural decay method from thorium-229 recovered from US Department of Energy uranium-233 stocks, and in 2026 broke ground on a $450 million Philadelphia facility intended to increase global capacity twentyfold, with production expected from 2029. Whether reactor, cyclotron and accelerator capacity can keep pace with a growing radioligand pipeline, without a repeat of the 2009-2010 shortage, is the open question this roadmap tracks.
- 1960s-2008historic
Reactor-dependent, HEU-based supply
Global molybdenum-99 supply concentrates in a small number of ageing, mostly HEU-fuelled research reactors (Canada's NRU, the Netherlands' HFR, Belgium's BR2, France's OSIRIS, South Africa's SAFARI-1), each serving large multi-country markets with no domestic US production.
- 2009-2010historic
The global Mo-99 shortage
NRU (Chalk River) and HFR both go offline for unplanned repairs at overlapping times, causing a worldwide shortage of molybdenum-99/technetium-99m that disrupts nuclear medicine imaging and prompts a US and international policy response to diversify supply.
- 2012-2018historic
Non-HEU domestic Mo-99 production
The American Medical Isotope Production Act (2012) directs the US Department of Energy/NNSA to fund non-HEU Mo-99 production. NorthStar Medical Radioisotopes' RadioGenix System, using neutron-capture production of Mo-99 at the University of Missouri Research Reactor, receives FDA approval on 8 February 2018, the first domestic, non-uranium Mo-99 production since the 1980s.
- 2018-2024current
Lutetium-177 demand outpaces capacity
Approvals of Lutathera (2018) and Pluvicto (2022) sharply increase demand for reactor-produced lutetium-177, straining both irradiation capacity and the enriched ytterbium-176 supply used for no-carrier-added Lu-177 production; multiple national reactor operators (ANSTO, IRE, NTP Radioisotopes) expand production lines.
- 2024-2026current
Accelerator-made actinium-225 reaches commercial scale
TerraPower Isotopes announces commercial-scale, weekly actinium-225 production from October 2024, using a natural decay method from thorium-229 recovered from US Department of Energy uranium-233 stockpiles in partnership with Isotek. In March 2026 the company announces a second, much larger facility in Philadelphia.
- 2026-2029emerging
Building twentyfold actinium-225 capacity
TerraPower Isotopes breaks ground on its $450m Bellwether Laboratory in Philadelphia in May 2026, intended to increase global actinium-225 production capacity twentyfold alongside expansion at its Everett, Washington site; the Pennsylvania state government contributes grant funding. Production is expected to begin in 2029.
- 2029+speculative
Speculative: a resilient, diversified isotope supply
Proposals under discussion include Western enrichment of ytterbium-176 to add a second Lu-177 supplier, a coordinated international reserve and shared schedule for medical isotope reactors, regional radiopharmacy hubs with harmonised transport rules for short-lived isotopes, and a global isotope supply observatory that forecasts shortages before they happen.
Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplierA coordinated reserve and shared schedule for the world's medical isotope reactorsRegional radiopharmacy hubs and harmonised transport rules for short-lived isotopesA global medical isotope supply observatory with forecasts and shortage alertsRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Probability ranges are named estimates that the claim is borne out on roughly a five-year horizon. They are meant to be argued with: propose a revision with your name and reasoning via a pull request to src/data/confidence.ts.
What to watch
Readouts, decisions and registry completion dates ahead. Each date is quoted from its source, not inferred; a missing date means no source states one.
Story
topReactor-dependent, HEU-based supply
Global molybdenum-99 supply concentrates in a small number of ageing, mostly HEU-fuelled research reactors (Canada's NRU, the Netherlands' HFR, Belgium's BR2, France's OSIRIS, South Africa's SAFARI-1), each serving large multi-country markets with no domestic US production.
The global Mo-99 shortage
NRU (Chalk River) and HFR both go offline for unplanned repairs at overlapping times, causing a worldwide shortage of molybdenum-99/technetium-99m that disrupts nuclear medicine imaging and prompts a US and international policy response to diversify supply.
Non-HEU domestic Mo-99 production
The American Medical Isotope Production Act (2012) directs the US Department of Energy/NNSA to fund non-HEU Mo-99 production. NorthStar Medical Radioisotopes' RadioGenix System, using neutron-capture production of Mo-99 at the University of Missouri Research Reactor, receives FDA approval on 8 February 2018, the first domestic, non-uranium Mo-99 production since the 1980s.
Lutetium-177 demand outpaces capacity
Approvals of Lutathera (2018) and Pluvicto (2022) sharply increase demand for reactor-produced lutetium-177, straining both irradiation capacity and the enriched ytterbium-176 supply used for no-carrier-added Lu-177 production; multiple national reactor operators (ANSTO, IRE, NTP Radioisotopes) expand production lines.
Where the radioactive atoms for imaging and therapy actually come from: ageing reactors, new accelerators, and a scramble for actinium.
A radioactive drug that seeks out PSMA on prostate cancer cells; the best-selling radiopharmaceutical ever.
Lutetium-177 dotatate was the first modern radioligand therapy (2018), for neuroendocrine tumours, and is now used in first line.
Accelerator-made actinium-225 reaches commercial scale
TerraPower Isotopes announces commercial-scale, weekly actinium-225 production from October 2024, using a natural decay method from thorium-229 recovered from US Department of Energy uranium-233 stockpiles in partnership with Isotek. In March 2026 the company announces a second, much larger facility in Philadelphia.
Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility to raise supply 20-fold.
Actinium-225 is the alpha-emitting atom behind the most promising next wave of radioligand therapies, and there is not enough of it. Almost all of it used to come from one decaying stock of thorium in a US national laboratory. New routes use accelerators and old radium.
Building twentyfold actinium-225 capacity
TerraPower Isotopes breaks ground on its $450m Bellwether Laboratory in Philadelphia in May 2026, intended to increase global actinium-225 production capacity twentyfold alongside expansion at its Everett, Washington site; the Pennsylvania state government contributes grant funding. Production is expected to begin in 2029.
Speculative: a resilient, diversified isotope supply
Proposals under discussion include Western enrichment of ytterbium-176 to add a second Lu-177 supplier, a coordinated international reserve and shared schedule for medical isotope reactors, regional radiopharmacy hubs with harmonised transport rules for short-lived isotopes, and a global isotope supply observatory that forecasts shortages before they happen.
The lutetium used in approved prostate and neuroendocrine cancer treatments is made from an enriched metal that comes mostly from Russia. Making it elsewhere would secure supply.
A handful of ageing research reactors make most cancer isotopes. Coordinating their maintenance and funding reserve capacity would prevent the shortages that stop treatments.
Radioactive cancer drugs decay while they travel and get stuck at borders. Regional production and simpler transport rules would get more doses to patients on time.
Nobody publishes how much cancer isotope is made, where, or when supply will fall short. A public observatory would let hospitals and investors plan.
Thousands of old radium sources sit in hospital and industrial storage. They are exactly the raw material needed to make actinium-225, the scarcest cancer isotope.
Similar pages
not linked directly; found by shared links- BottleneckMolybdenum-99 supply
Shares Nordion (Sotera Health), ANSTO (Australian Nuclear Science and Technology Organisation), SHINE Technologies, A coordinated reserve and shared schedule for the world's medical isotope reactors.
- BottleneckManufacturing cost and time for living and radioactive medicines
Shares A coordinated reserve and shared schedule for the world's medical isotope reactors, Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes, Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier, A global medical isotope supply observatory with forecasts and shortage alerts.
- BottleneckEnriched target material for therapeutic isotopes
Shares NTP Radioisotopes, Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- BottleneckActinium-225 supply
Shares NorthStar Medical Radioisotopes, A global medical isotope supply observatory with forecasts and shortage alerts, Recover legacy radium-226 sources worldwide as the feedstock for actinium-225, TerraPower Isotopes.
- CompanyEckert & Ziegler
Shares Actinium-225 supply: thorium stocks, accelerators and radium targets, Radiopharmacy and cyclotron networks, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- CompanyNiowave
Shares Molybdenum-99, Actinium-225 supply: thorium stocks, accelerators and radium targets, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- CompanyBWXT Medical
Shares Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Technetium-99m.
- CompanyITM Isotope Technologies Munich
Shares Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier, Actinium-225 supply: thorium stocks, accelerators and radium targets, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).